MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$7,538,687
EPS
-$0.13
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development expenses
5,232,541 8,449,085.5* 4,968,596 4,926,936
Acquisition-related costs (note 5)
-919,904.5* --
General and administrative expenses
2,297,358 -2,481,389.5* 1,761,007 4,949,020
Operating loss
7,529,899 6,887,600.5* 6,729,603 9,875,956
Employee retention tax credit
-28,393.5* --
Grant income
-22,077* 138,299 322,655
Interest expense
27,974 575,687* 16,532 -
Interest income
21,275 82,944* 6,060 29,466
Other expense
--185,019 -
Change in fair value of kineta merger holdback shares
-2,263,585.75* -315,660 -
Loss on kineta employee separation payments assumed from merger
-46,254.75* --
Total other (expense) income
-6,699 1,775,058.5* -372,852 352,121
Net loss
-7,536,598 -5,112,542* -7,102,455 -9,523,835
Series a preferred cash dividend
2,089 2,089* 2,089 2,089
Deemed dividend on warrant modifications
-0* --
Net loss attributable to common stockholders
-7,538,687 -5,114,631 -7,104,544 -9,525,924
Basic EPS
-0.13 -0.105 -0.14 -0.21
Diluted EPS
-0.13 -0.105 -0.14 -0.21
Basic Average Shares
60,010,237 48,560,063 50,666,430 44,555,095
Diluted Average Shares
60,010,237 48,560,063 50,666,430 44,555,095
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$7,538,687 Net loss-$7,536,598 Series a preferred cashdividend$2,089 Operating loss$7,529,899 Total other (expense)income-$6,699 Interest income$21,275 Research and developmentexpenses$5,232,541 General andadministrative expenses$2,297,358 Interest expense$27,974

TuHURA Biosciences, Inc. NV (HURA)

TuHURA Biosciences, Inc. NV (HURA)